Form 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 21, 2004

 

 

BioMarin Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware   000-26727   68-0397820

(State or other jurisdiction of

incorporation or organization)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

371 Bel Marin Keys Boulevard, Suite 210, Novato, California   94949
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (415) 506-6700

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 8.01. Other Events.

 

On September 21, 2004, BioMarin Pharmaceutical Inc. (the “Registrant”), issued a press release regarding revised financial guidance for 2004. The Registrant’s press release issued on September 21, 2004 is attached hereto as Exhibit 99.1.

 

Item 9.01. Financial Statements, Pro Forma Financial Statements and Exhibits.

 

  (a) Financial Statements of Business Acquired.

 

Not Applicable.

 

  (b) Pro Forma Financial Information.

 

Not Applicable.

 

  (c) Exhibits.

 

Exhibit 99.1  

Press Release of the Registrant dated September 21, 2004.

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

BioMarin Pharmaceutical Inc.,

a Delaware corporation

Date: September 21, 2004

  

By:

  

/s/ Jeffrey H. Cooper

       

Jeffrey H. Cooper

       

Chief Financial Officer

EXHIBIT INDEX

 

Exhibit No.
  

Description

Exhibit 99.1   Press Release of the Registrant dated September 21, 2004.